RHEACELL INNOVATIVE STEM CELL THERAPIES
LIVE

Serial Number

79307004

Owner

RHEACELL GmbH & Co. KG

Attorney

Sean K. Owens

Filing Date

Dec 11, 2020

Add to watchlist:

No watchlists yet
View on USPTO

RHEACELL INNOVATIVE STEM CELL THERAPIES Trademark

Serial Number: 79307004 • Registration: 6696110

RHEACELL INNOVATIVE STEM CELL THERAPIES is a trademark filed by RHEACELL GmbH & Co. KG on December 11, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

RHEACELL GmbH & Co. KG (9 trademarks)

Im Neuenheimerfeld 517

Entity Type: 28

Trademark Details

Filing Date

December 11, 2020

Registration Date

April 12, 2022

Published for Opposition

January 25, 2022

Goods & Services

Pharmaceutical drug development; scientific and technological services, namely medical and pharmaceutical research services and technical research in the field of pharmaceutical studies, regenerative medicine and tissue engineering; research and development services in the fields of cell diagnostics and research and development services relating to new products for others in the field of therapy and surgical and medical instruments; industrial analysis and research services, namely analysis of industrial fluids and medical research, chemical analysis; scientific research for medical purposes in the field of stem cell therapies; stem cell research; scientific and medical research and development in the field of stem cells; scientific research, testing and analysis services of the services of others to determine conformity with certification standards and in the field of regenerative medicine and tissue engineering; scientific research for medical purposes; medical research; research in the field of biotechnology; research in the field of gene therapy; research and development in the field of immunology; research and development in the field of antibodies; research and development in the field of antibody technology; research and development in the field of bacteriology; product research and development in the field of gene expression systems; research and development in the field of vaccines; research and development services for the pharmaceutical industry; research and development services in the field of biotechnology

Medical services; medical diagnostic services for carrying out tests and analyses; medical assistance; medical clinic services; hospital services; plastic and cosmetic surgery; medical therapies, namely, stem cell therapy for treating medical conditions; medical services being human cells and tissue banks, stem cell banks and bone marrow banks, medical services in the field of regenerative medicine and medical analysis services relating to the treatment of patients in the field of tissue engineering; medical services being banks of human tissue and stem cells, medical services in the field of regenerative medicine and medical analysis services relating to the treatment of patients in the field of tissue engineering; medical services in the nature of stem cell banks for medical transplantation; medical services in the nature of cultured stem cell banks for medical transplantation

Drugs, namely, drug delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceuticals; pharmaceutical and veterinary preparations for the treatment of skin diseases, pharmaceutical and veterinary preparations for the treatment of vertigo, pharmaceutical and veterinary preparations for the treatment of nausea, pharmaceutical and veterinary preparations for the treatment of vomiting, pharmaceutical and veterinary preparations for the treatment of migraine, pharmaceutical and veterinary preparations for the treatment of disease and disorders of the respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the nervous system, the musculoskeletal system, the urinary system, the integumentary system, and the reproductive system, pharmaceutical and veterinary preparations for the treatment of blood diseases and disorders, pharmaceutical and veterinary preparations, namely, antibiotics, immune suppressants, anti-inflammatory preparations, pharmaceutical and veterinary preparations for wound healing, pharmaceutical and veterinary preparations for anti-aging, namely, stem cells for medical and medical aesthetic purposes, fibroblast cells for medical and medical aesthetic purposes, surgical tissue implants comprised of living tissues obtained from fibroblasts; diagnostic agents for medical purposes; diagnostic preparations for medical and biomedical purposes; pharmaceutical cell preparations for medical use for the treatment of skin diseases, vertigo, nausea, vomiting, migraine, disease and disorders of the respiratory system, disease and disorders of the gastrointestinal system, disease and disorders of the endocrine system, disease and disorders of the cardiovascular system, disease and disorders of the nervous system, disease and disorders of musculoskeletal system, disease and disorders of urinary system, disease and disorders of integumentary system, disease and disorders of the reproductive system, blood diseases and disorders; sterilizing substances for medical use; sterilizing substances for biomedical purposes; live implants comprising of live tissues for pharmaceutical purposes; biochemical and chemical products, namely, biochemical preparations for the treatment of skin diseases and chemical reagents for medical use; biochemical and chemical products, namely, biochemical preparations for the treatment of skin diseases and chemical reagents for pharmaceutical purposes; biochemical and chemical products for pharmaceutical or medical purposes, namely, biochemical preparations for the treatment of skin diseases, vertigo, nausea, vomiting, migraine, disease and disorders of the respiratory system, disease and disorders of the gastrointestinal system, disease and disorders of the endocrine system, disease and disorders of the cardiovascular system, disease and disorders of the nervous system, disease and disorders of musculoskeletal system, disease and disorders of urinary system, disease and disorders of integumentary system, and disease and disorders of the reproductive system, blood diseases and disorders for diagnostic purposes; proteins being protein supplements for medical purposes; biological preparations for medical and veterinary purposes, and pharmaceutical and veterinary preparations, all for external use for the treatment of skin diseases, wounds, ulcers, burns and surgical wounds; biological, pharmaceutical and veterinary preparations for skin care for medical purposes; medical dressings; pharmaceutical preparations for wound treating and healing; biological, pharmaceutical and veterinary preparations for the treatment of chronic wounds, ulcers, burns and surgical wounds; stem cells for medical purposes; stem cells for veterinary purposes; stem cells for aesthetic purposes for medical use; somatic stem cell therapeutics for medical purposes; pharmaceutical implants, namely, implantable surgery human allograft bones, biological bone tissue grafts, cells for medical use, biological bone marrow tissue; surgical implants comprised of living stem cells; surgical implants comprised of living fibroblasts tissue cells; biological human skin and bone tissue intended for subsequent implantation; cell growth media for culturing cells for medical purposes; pharmaceutical preparations for tissue regeneration; vascular grafts; living tissue, namely, vascular grafts; biotechnologically engineered tissue products, namely, tissue cells in sheet form and plasters for wound healing and treating burns for medical purposes, biological eye lens tissue grafts, biological bone tissue grafts

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
May 14, 2026 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 20, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 26, 2022 FICS
FINAL DISPOSITION PROCESSED
Aug 26, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 12, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 12, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 25, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jan 25, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Jan 22, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 5, 2022 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 5, 2022 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 5, 2022 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 21, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 21, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 21, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 21, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 21, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 7, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 6, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 6, 2021 TROA
REFUSAL PROCESSED BY IB
Jun 28, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 9, 2021 RFCS
REFUSAL PROCESSED BY MPU
Jun 9, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 8, 2021 RFCR
NON-FINAL ACTION WRITTEN
Jun 7, 2021 CNRT
ASSIGNED TO EXAMINER
Jun 3, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 26, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 22, 2021 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 18, 2021 REPR